Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging  Konstantinos Karmiris, Didier Bielen, Dirk Vanbeckevoort, Séverine Vermeire, Georges Coremans, Paul Rutgeerts, Gert Van Assche  Clinical Gastroenterology and Hepatology  Volume 9, Issue 2, Pages 130-136.e1 (February 2011) DOI: 10.1016/j.cgh.2010.10.022 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Clinical outcome of IFX therapy in our cohort of pfCD patients. Clinical Gastroenterology and Hepatology 2011 9, 130-136.e1DOI: (10.1016/j.cgh.2010.10.022) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 MRI score change short-term, mid-term, and long-term in pfCD patients under IFX therapy. Clinical Gastroenterology and Hepatology 2011 9, 130-136.e1DOI: (10.1016/j.cgh.2010.10.022) Copyright © 2011 AGA Institute Terms and Conditions

Figure 3 Individual MRI score change in the total cohort (A) and according to complete (B), partial (C), and absent (D) clinical response. Clinical Gastroenterology and Hepatology 2011 9, 130-136.e1DOI: (10.1016/j.cgh.2010.10.022) Copyright © 2011 AGA Institute Terms and Conditions

Figure 4 MRI images of a perianal horseshoe fistula in a young male patient with CD before and 3 months and 1 year after IFX therapy. Note that the inflammatory component (T2 hyperintensity and collections) markedly improved, but that the fistula track is still present after 1 year. Clinical Gastroenterology and Hepatology 2011 9, 130-136.e1DOI: (10.1016/j.cgh.2010.10.022) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 1 Midterm MRI score change in patients in remission in comparison with those with draining fistulas. Clinical Gastroenterology and Hepatology 2011 9, 130-136.e1DOI: (10.1016/j.cgh.2010.10.022) Copyright © 2011 AGA Institute Terms and Conditions